CIPLA LTD vs ONYX BIOTEC LIMITED

A side-by-side comparison of CIPLA LTD (CIPLA) and ONYX BIOTEC LIMITED (ONYX) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, CIPLA LTD leads CIPLA vs ONYX on 10 of 14 metrics (1 tied). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

29.54
P/E ratio
13.77
3.42
P/B ratio
1.20
0.90%
Dividend yield
0.00%
₹48.02
EPS
₹2.73

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

11.60%
Return on equity
-0.38%
15.00%
Return on capital
12.16%
21.00%
EBITDA margin
16.76%
13.71%
Net margin
7.99%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

7.37%
Revenue CAGR (3Y)
20.72%
10.88%
Profit CAGR (3Y)

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹1.15L Cr
Market cap
₹67 Cr
₹28,163 Cr
Revenue
₹62 Cr
₹3,862 Cr
Net profit
₹5 Cr
0.02
Debt / equity
0.27
CIPLA LTD
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 25.7%"]
  • ["The company has delivered a poor sales growth of 8.01% over past five years.", "Promoter holding has decreased over last 3 years: -4.34%"]
ONYX BIOTEC LIMITED
  • ["Company has low interest coverage ratio.", "Company has a low return on equity of 6.49% over last 3 years."]
CIPLA LTD full analysis ONYX BIOTEC LIMITED full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.

CIPLA LTD vs ONYX BIOTEC LIMITED: Share Price, Valuation & Which to Buy | DocStoX